Fig. 2.

Combination of trastuzumab and pertuzumab enhanced monocyte phagocytosis by increasing avidity. A half-log titration series evaluating trastuzumab, pertuzumab, trastuzumab + pertuzumab, and isotype control were used to evaluate (a) tumor cell death and (b) phagocytosis. c Staining of HCC1419 with pertuzumab and trastuzumab which was detected with a secondary goat anti-human PE antibody. All samples were performed in triplicate; means ± SEM and regression line are plotted on the graph. Two-way ANOVA with Sidak’s multiple comparisons test was used to determine significance. Asterisk represents significance between trastuzumab and pertuzumab compared to trastuzumab or pertuzumab. d Quantitative flow cytometry was used to measure FcγRII and FcγRIIIa expression